To further explore the mechanism of synergistic function between abivertinib and venetoclax, we measured the protein expression levels of BTK (Fig. 4C) and its downstream proteins (Fig. S3) in AML cell lines in different treatment groups. The gene discussed is BTK; the disease is acute myeloid leukemia.